Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Ardsley Advisory Partners LP

Ardsley Advisory Partners LP raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 16.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 580,000 shares of the company’s stock after acquiring an additional 80,000 shares during the quarter. Teva Pharmaceutical Industries accounts for about 2.0% of Ardsley Advisory Partners LP’s portfolio, making the stock its 11th biggest holding. Ardsley Advisory Partners LP’s holdings in Teva Pharmaceutical Industries were worth $18,102,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its position in shares of Teva Pharmaceutical Industries by 1.1% in the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after buying an additional 4,820,000 shares during the last quarter. Finally, Norges Bank acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $1,098,060,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer owned 20,016 shares of the company’s stock, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $32.59 on Thursday. The business has a fifty day moving average of $33.46 and a 200-day moving average of $32.17. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The firm has a market cap of $37.47 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.36 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Bank of America raised their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Truist Financial raised their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.